PackHealth: Asthma Engagement Tool

Duke University

Status

Completed

Conditions

Asthma

Treatments

Behavioral: Patient engagement toolkit

Study type

Interventional

Funder types

Other

Identifiers

NCT02413684

Pro00057939

Details and patient eligibility

About

The purpose of this study is to test the impact of an innovative patient engagement solution on patient's quality of life and asthma-related outcomes, and evaluate the correlation between a patient reported outcome measure and clinical outcomes.

Full description

Patient engagement is a critical part of improving patient care and outcomes. Current patient engagement strategies only focus on the patient-physician interaction and have been shown to be ineffective.

The need for a comprehensive approach to patient engagement is no different among patients with asthma as it is in any other chronic condition. Patients with asthma must make complicated health decisions daily that impact their social and occupational activities, quality of life, and treatment adherence. Obtaining, communicating, processing, and understanding non- biased health information are crucial in making appropriate and informed treatment decisions.

Pack Health LLC and Duke will develop a patient engagement toolkit known as "Packs" to help empower and engage patients. These disease-specific, evidence-based kits are scientifically designed to improve patient involvement in their own care. Each Pack draws on the science of change management and patient activation and contains three categories of materials

Enrollment

53 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with a physician diagnosis of asthma for at least the previous 12 months.
Asthma that is not well controlled by NAEPP guidelines.
Ability and willingness to provide informed consent

Exclusion criteria

Significant alcohol consumption of more than three alcoholic drinks per day or active substance abuse.
Chronic disease (other than asthma) that in the opinion of the investigator would prevent participation in the trial or put the participant at risk by participation e.g. chronic diseases of the lung (other than asthma), heart, liver, kidney, endocrine or nervous system or immunodeficiency that are not well addressed or controlled.
A diagnosis of cancer with ongoing treatment.
Any terminal illness or conditions that results in a life expectancy less than one year.